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Abstract
Background: The multiple disease domains affected in psoriatic arthritis (PsA) may make composite endpoints
appropriate for assessing changes in disease activity over time. Tofacitinib is an oral Janus kinase inhibitor for the
treatment of PsA. Data from two phase 3 studies of patients with PsA were used to evaluate the effect of tofacitinib
on composite endpoints.
Methods: Oral Psoriatic Arthritis triaL (OPAL) Broaden was a 12-month study of tumor necrosis factor inhibitor
(TNFi)-naïve patients with an inadequate response to at least one conventional synthetic disease-modifying anti-
rheumatic drug; OPAL Beyond was a 6-month study of patients with inadequate response to TNFi. Patients with
active PsA received tofacitinib 5 or 10 mg doses twice daily (BID), adalimumab 40 mg subcutaneous injection once
every 2 weeks (OPAL Broaden only), or placebo advancing at month 3 to tofacitinib 5 or 10 mg BID. The disease-
specific composites were Psoriatic Arthritis Disease Activity Score (PASDAS), Disease Activity Index for Reactive
Arthritis/Psoriatic Arthritis (DAPSA), and Composite Psoriatic Disease Activity Index (CPDAI). Change from baseline in
composite endpoints was also assessed for minimal disease activity (MDA) responders versus non-responders.
Results: Overall, 422 patients from OPAL Broaden and 394 patients from OPAL Beyond were treated. The mean
changes from baseline to month 3 for tofacitinib 5 mg BID, tofacitinib 10 mg BID (standard error; effect size) were
OPAL Broaden: PASDAS, −2.0 (0.14; 1.73), −2.4 (0.14; 2.4); DAPSA, −20.2 (1.72; 0.9), −24.4 (1.73; 1.23); and CPDAI, −2.9
(0.34; 1.03), −4.2 (0.36; 1.53); OPAL Beyond: PASDAS, −1.9 (0.14; 1.53), −2.1 (0.14; 1.84); DAPSA, −22.5 (1.67; 0.81),
−21.0 (1.70; 0.84); and CPDAI, −3.3 (0.31; 1.41), −3.4 (0.31; 1.45). Greater changes from baseline to month 3 (P ≤0.05)
were seen with both doses of tofacitinib versus placebo for all endpoints except CPDAI for tofacitinib 5 mg BID in
OPAL Broaden. Effect sizes generally increased from 3 to 6 months. Mean changes from baseline were greater in
MDA responders than MDA non-responders for all composite endpoints across all time points and treatments.
Conclusions: This analysis suggests that disease-specific composite measures are appropriate for evaluating
treatment efficacy on multiple disease domains in PsA.
Trial registration: OPAL Broaden: ClinicalTrials.gov Identifier: NCT01877668, first posted June 12, 2013; OPAL
Beyond: ClinicalTrials.gov Identifier: NCT01882439, first posted June 20, 2013.
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Background
Psoriatic arthritis (PsA) is a chronic, systemic, immune-
mediated inflammatory disease with multiple disease
manifestations, including peripheral arthritis, enthesitis,
dactylitis, spondylitis, and psoriatic skin and nail disease
[1–3]. Owing to the multiple diverse disease manifesta-
tions involved in PsA, the Group for Research and
Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)
bases its treatment recommendations on the domains
affecting an individual [1]. Consequently, composite end-
points, which allow the assessment of multiple clinical
outcomes in a single instrument, have been suggested to
be particularly useful to assess changes in the multiple dis-
ease domains of PsA over time [3, 4]. Composite end-
points also have the potential to simplify statistical testing
in clinical trials as a summary or total score is usually
generated, thus requiring only a single hypothesis test,
thereby avoiding issues with multiplicity and allowing
for appropriate statistical power with relatively small
numbers of patients [5].
A number of composite endpoints have been developed
for PsA in order to assess multiple aspects of disease
activity and identify patients who have achieved treatment
targets of remission or minimal disease activity (MDA).
Available instruments incorporate different types of
assessments, including clinical (for example, tender and
swollen joint counts [TJC and SJC]), laboratory (for
example, C-reactive protein [CRP]), and patient-reported
outcome (PRO) (for example, Health Assessment
Questionnaire-Disability Index [HAQ-DI]) endpoints. Al-
though there is no clear agreement on a standardized
composite assessment approach that provides the optimal
combination of individual variables [6], agreement has
now been reached on a core domain set of variables that
should be included [7].
Tofacitinib is an oral inhibitor of the Janus kinase
(JAK) family for the treatment of PsA. Tofacitinib pre-
ferentially inhibits signaling via JAK3 or JAK1 (or both)
with functional selectivity over JAK2 [8]. The efficacy
and safety of tofacitinib 5 and 10 mg twice daily (BID)
have been demonstrated in patients with PsA with an in-
adequate response to conventional synthetic disease-
modifying anti-rheumatic drugs (csDMARDs) in Oral
Psoriatic Arthritis triaL (OPAL) Broaden [9] and in pa-
tients with PsA who were tumor necrosis factor inhibitor
(TNFi)-inadequate responders (IRs) in OPAL Beyond
[10]. In both studies, tofacitinib had greater efficacy than
placebo on the basis of the primary endpoints: a higher
proportion of patients receiving tofacitinib than placebo
achieved greater than or equal to 20% improvement ac-
cording to the criteria of the American College of
Rheumatology (ACR20 response) at month 3, and the
mean change from baseline to month 3 in HAQ-DI
score was greater in patients receiving tofacitinib versus
placebo at month 3. In addition, between 21% and 26%
of patients receiving tofacitinib and between 7% and
15% of patients receiving placebo had MDA responses at
month 3 in OPAL Broaden and OPAL Beyond [9, 10].
This analysis evaluated the effect of tofacitinib on three
disease-specific composite endpoints in patients with
PsA by using data from the two placebo-controlled,
double-blind, multicenter, global phase 3 studies of
tofacitinib detailed above: OPAL Broaden and OPAL
Beyond [9, 10].
Methods
Patients
Details of patient populations and study designs for both
OPAL Broaden (A3921091; ClinicalTrials.gov Identifier:
NCT01877668) and OPAL Beyond (A3921125; Clini-
calTrials.gov Identifier: NCT01882439) have been pub-
lished in detail [9, 10]. In brief, for inclusion in either
OPAL Broaden or OPAL Beyond, patients were required
to have active PsA with a duration of at least 6 months,
to fulfill ClASsification criteria for Psoriatic ARthritis
(CASPAR) at screening, and to have evidence of active
arthritis with both a TJC and SJC of three or higher.
Patients in OPAL Broaden had an inadequate response
to at least one csDMARD and were TNFi-naïve, whereas
patients in OPAL Beyond had an inadequate response to
at least one TNFi. The primary endpoints in both studies
were ACR20 response rate and change from baseline in
HAQ-DI score at month 3.
Study design
OPAL Broaden was a 12-month study in which patients
were randomly assigned 2:2:2:1:1 to receive tofacitinib
5 mg BID, tofacitinib 10 mg BID, adalimumab 40 mg
subcutaneous (SC) injection once every 2 weeks (Q2W),
placebo advancing to tofacitinib 5 mg BID at month 3,
or placebo advancing to tofacitinib 10 mg BID at month
3. OPAL Beyond was a 6-month study in which patients
were randomly assigned 2:2:1:1 to receive tofacitinib
5 mg BID, tofacitinib 10 mg BID, placebo advancing to
tofacitinib 5 mg BID at month 3, or placebo advancing
to tofacitinib 10 mg BID at month 3. In both studies, pa-
tients also received one concomitant treatment with a
stable dose of either methotrexate or another csDMARD
(for example, sulfasalazine or leflunomide).
Assessments
Three disease-specific composite endpoints are discussed
in this analysis. The Psoriatic Arthritis Disease Activity
Score (PASDAS) (score range of 0–10) includes the
following components: patient’s global joint and skin
assessment (visual analog scale; VAS [in millimeters]); phy-
sician’s global assessment of PsA (VAS [in millimeters]);
SJC (66 joints) and TJC (68 joints); Leeds Enthesitis Index
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(LEI) score; tender dactylitic digit score; physical compo-
nent summary (PCS) score of the 36-item short-form sur-
vey version 2 (SF-36v2 acute, norm-based scores); and
CRP (in milligrams per liter) (Table 1) [11]. The Disease
Activity Index for Reactive Arthritis/Psoriatic Arthritis
(DAREA/DAPSA) (score range not defined; referred to as
DAPSA herein) includes the components SJC (66 joints)
and TJC (68 joints); patient’s global assessment of arthritis
and patient’s pain assessment (both measured by VAS [in
millimeters]); and CRP (in milligrams per liter) (Table 1)
[6]. The Composite Psoriatic Disease Activity Index
(CPDAI) (score range of 0–15) includes the components
peripheral arthritis (SJC, TJC, and HAQ-DI); skin disease
(Psoriasis Area and Severity Index [PASI] and Dermatology
Life Quality Index [DLQI]); enthesitis (LEI score and
HAQ-DI); dactylitis (number of digits and HAQ-DI); and
spinal disease (Bath Ankylosing Spondylitis Disease Activ-
ity Index and Ankylosing Spondylitis Quality of Life
[ASQoL]) (Table 1) [12]. For each of these composite end-
points, a higher score indicates higher disease activity. For
comparison, a non-disease-specific composite outcome
measure was also assessed: the three-component Disease
Activity Score using 28 joints with CRP (DAS28–3 [CRP];
score range of 0–9.4, a higher score corresponds to worse
symptoms) includes the components SJC (28 joints)
and TJC (28 joints) and CRP (in milligrams per liter)
(Table 1) [13].
Statistical analysis
The full analysis set (FAS) comprised all patients who
were randomly assigned to the study and received at
least one dose of study medication. Changes from base-
line analyses were based on a repeated measures model,
without imputation for missing values in the FAS, with
the fixed effects of treatment, visit, treatment-by-visit
interaction, geographic location, and baseline value; an
unstructured covariance matrix was used. For results up
to month 3, patients randomly assigned to the two pla-
cebo sequences were combined into a single placebo
group. The repeated measures model included data from
all visits up to month 3 for the treatment groups of tofaci-
tinib 5 mg BID, tofacitinib 10 mg BID, adalimumab 40 mg
SC Q2W (OPAL Broaden only), and placebo. For results
beyond month 3 to the end of study, the two placebo
sequences were analyzed separately. The calculation of ef-
fect sizes and standardized response means for treatment
groups of tofacitinib 5 mg BID, tofacitinib 10 mg BID, and
adalimumab (OPAL Broaden only) at months 3, 6, and 12
(OPAL Broaden only at month 12) was based on patients
with greater than or equal to 3% baseline psoriasis body
surface area (BSA) in the FAS in order to permit compari-
son based on the same set of patients, with no missing
values for any of the three disease-specific composite end-
points at baseline or months 3, 6, and 12 (OPAL Broaden
only at month 12).
The effect size for a given composite endpoint at a
time point was defined as (mean at baseline – mean at
time point)/(standard deviation [SD] at baseline). The
standardized response mean for a given composite
endpoint at a time point was defined as (mean at base-
line – mean at time point)/(SD of change from baseline
at time point). Effect size and standardized response
mean are unitless measures and are adjusted for the
endpoints’ variability, which allows comparisons to be
made. For both effect sizes and standardized response
means, levels of responsiveness have been proposed as
small (≥0.20 to <0.5), moderate (≥0.50 to <0.8), and large
(≥0.80), respectively [3, 14].
In order to investigate the relative strength of the
composite endpoints in predicting MDA response at a
given time point, multiple logistic regression was used to
model MDA response as a dependent variable and the
mean changes from baseline of the three disease-specific
composite endpoints at the same time point as predic-
tors. The estimated slope coefficient from this regression
model is the change in log-odds of MDA response
resulting from a 1-unit increase in change from baseline
of the composite endpoint. It represents the strength of
association between the composite endpoint and MDA
response and is standardized (STB, range unbounded) to
adjust for the variability of the composite endpoint to
permit comparison of their associations with MDA re-
sponse. In order to compare the correlations of the three
disease-specific composite endpoints with MDA re-
sponse, another standardized measure related to STB
above, called logistic pseudo partial correlation (denoted
as R, range of −1 to 1), was also calculated [15]. A value
of R closer to 1 or −1 indicates strong correlation,
Table 1 Components of the composite endpoints PASDAS, DAPSA, CPDAI, and DAS28–3(CRP)
Skin manifestations Enthesitis Dactylitis Joints Axial PROs
PASDAS [11] ✓ ✓ ✓ ✓ ✓
DAPSA [6] ✓ ✓
CPDAI [12] ✓ ✓ ✓ ✓ ✓ ✓
DAS28–3(CRP) [13] ✓
Abbreviations: CPDAI Composite Psoriatic Disease Activity Index, DAPSA Disease Activity Index for Psoriatic Arthritis, DAS28–3(CRP) 3-component Disease Activity
Score using 28 joints with C-reactive protein, PASDAS Psoriatic Arthritis Disease Activity Score, PRO patient-reported outcomes
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whereas a value of 0 indicates lack of correlation. This re-
gression analysis was performed separately for months 3,
6, and 12 (OPAL Broaden only for month 12) and separ-
ately for tofacitinib 5 mg BID, 10 mg BID, and adalimu-
mab 40 mg SC Q2W. These analyses included the same
set of patients with baseline psoriasis BSA of greater than
or equal to 3% in the FAS with no missing values for any
of the three disease-specific composite endpoints and
MDA at months 3, 6, and 12 (OPAL Broaden only at
month 12). MDA was defined as any five of the following
seven criteria being met: TJC ≤1, SJC ≤1, PASI score ≤1 or
psoriasis BSA ≤3%, patient arthritis pain (VAS) ≤15 mm,
patient’s global assessment of arthritis (VAS) ≤20 mm,
HAQ-DI ≤0.5, tender entheseal points (using LEI) ≤1 [16].
The PASDAS response rate was calculated at months
3, 6, and 12 (OPAL Broaden only for month 12) as the
percentage of patients who had a good response (defined
as a PASDAS score of less than or equal to 3.2 and a de-
crease from baseline in PASDAS score of greater than or
equal to 1.6 at the relevant time point for patients with
baseline PASDAS score of greater than 3.2 in FAS) [17].
Non-responder imputation was applied, and a missing
response was treated as non-response.
The derivation of the composite endpoints was
pre-specified in the original study protocols and statis-
tical analysis plans; except for analysis using a repeated
measures model, all analyses were performed post
hoc. P values are reported for comparisons with placebo
in repeated measures model analyses and for testing slope
coefficients in multiple logistic regression analyses without
adjustment for multiplicity. The significance level was set
at two-sided, less than or equal to 0.05.
Results
Patients
The FAS comprised 422 patients from OPAL Broaden
and 394 patients from OPAL Beyond (Table 2). Demo-
graphics and baseline disease characteristics have been
published previously [9, 10]. Baseline values for compos-
ite endpoints were generally similar across treatment
groups and studies (Table 2).
Composite endpoint outcomes
PASDAS
At baseline, mean PASDAS scores ranged from 5.92 to
6.43 across treatment groups in the OPAL Broaden and
OPAL Beyond studies (Table 2). There were significantly
greater improvements, as indicated by the least squares
(LS) mean change from baseline in PASDAS score, with
tofacitinib 5 and 10 mg BID versus placebo as early as
month 1, continuing to month 3. Following advance-
ment from placebo to tofacitinib treatments at month 3,
patients showed similar improvements in disease activity
at month 6 to those observed in patients receiving
tofacitinib 5 or 10 mg BID throughout (Additional file 1:
Table S1 and Fig. 1a); this improvement was maintained
until the end of the 12-month OPAL Broaden study
(Table 2 and Fig. 1a) and was larger in patients in the
placebo advancing to tofacitinib 10 mg BID group
than the placebo advancing to tofacitinib 5 mg BID
group. In OPAL Broaden, the mean absolute PASDAS
scores decreased to 3.29 and 3.05 with tofacitinib 5
and 10 mg BID, respectively, at month 12, and in
OPAL Beyond the mean PASDAS scores at month 6
were 3.87 and 3.97 with tofacitinib 5 and 10 mg BID,
respectively (Table 2). In OPAL Broaden, decreases
from baseline in PASDAS scores were also observed
in patients receiving adalimumab 40 mg SC Q2W
from month 1 and were maintained to month 12
(Additional file 1: Table S1 and Fig. 1a).
PASDAS response rates
The percentage of PASDAS responders increased with
time on treatment in both studies and with both doses
of tofacitinib (Fig. 2). A similar percentage of patients
initially randomly assigned to receive placebo were PAS-
DAS responders compared with those patients receiving
tofacitinib throughout at month 6 in OPAL Beyond and
month 12 in OPAL Broaden, following advancement
from placebo to active treatment with tofacitinib at
month 3 (Fig. 2).
DAPSA
At baseline, mean DAPSA scores in the two studies
ranged from 38.52 to 51.54 across treatment groups
(Table 2). In OPAL Broaden, significantly greater LS
mean changes from baseline in the DAPSA score (indi-
cating improvement) were observed versus placebo for
tofacitinib 10 mg BID from week 2 and for tofacitinib
5 mg BID from month 2, and differences were main-
tained to month 3 for both doses (Fig. 1b). In OPAL
Beyond, significantly greater improvements, as indi-
cated by LS mean changes from baseline in the
DAPSA score, were observed with both doses of tofa-
citinib versus placebo from week 2 throughout the
placebo-controlled period (Fig. 1b). The LS mean
changes from baseline in the DAPSA score showed
further decreases to month 6 with tofacitinib treat-
ment in both studies (Fig. 1b), and the improvement
was maintained to month 12 in OPAL Broaden (Additional
file 1: Table S1 and Fig. 1b). At month 12 in OPAL
Broaden, the mean absolute DAPSA scores were 15.14 and
13.21 with tofacitinib 5 and 10 mg BID, respectively,
whereas in OPAL Beyond they decreased to 20.69 and
28.30 at month 6 with tofacitinib 5 and 10 mg BID,
respectively (Table 2). At month 6 in both studies
and month 12 in OPAL Broaden, following advance-
ment from placebo to tofacitinib at month 3, patients
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showed similar improvements in DAPSA scores to
patients receiving tofacitinib throughout (Table 2 and
Fig. 1b). Patients receiving adalimumab 40 mg SC
Q2W showed decreases from baseline in DAPSA
scores throughout both OPAL Broaden and OPAL Be-
yond (Table 2 and Fig. 1b).
CPDAI
At baseline, mean CPDAI scores ranged from 9.6 to 10.7
across studies and treatment groups (Table 2). For
CPDAI, significant improvements in LS mean change
from baseline were seen for tofacitinib 10 mg BID but
not tofacitinib 5 mg BID versus placebo at months 1 and
3 in OPAL Broaden (Fig. 1c). Significant improvements
in LS mean change from baseline in CPDAI score versus
placebo at months 1 and 3 were reported for patients re-
ceiving tofacitinib 5 and 10 mg BID in OPAL Beyond
(Fig. 1c). Decreases in LS mean change from baseline in
CPDAI score with both doses of tofacitinib were main-
tained at months 6 and 12 (Fig. 1c). In OPAL Broaden,
a
b
c
Fig. 1 LS mean change from baseline in (a) PASDAS, (b) DAPSA, and (c) CPDAI. For complete data, see Additional file 1: Table S1. *P ≤0.05,
**P <0.01, ***P <0.001 versus placebo. Abbreviations: BID twice daily, CPDAI Composite Psoriatic Disease Activity Index, DAPSA Disease Activity
Index for Psoriatic Arthritis, LS least squares, OPAL Oral Psoriatic Arthritis triaL, PASDAS Psoriatic Arthritis Disease Activity Score, Q2W once every
2 weeks, SC subcutaneous, SE standard error
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the mean absolute CPDAI scores with tofacitinib 5 and
10 mg BID at month 12 were 5.1 and 4.4, respectively,
and in OPAL Beyond they were 6.3 and 6.5, respectively,
at month 6 (Table 2). Patients who advanced from pla-
cebo to tofacitinib treatments at month 3 showed similar
improvements in CPDAI absolute scores and LS mean
change from baseline in CPDAI at month 12 in OPAL
Broaden and month 6 in OPAL Beyond to patients re-
ceiving tofacitinib 5 or 10 mg BID throughout (Table 2
and Fig. 1c). In OPAL Broaden, patients receiving adali-
mumab 40 mg SC Q2W showed improvements from
baseline in CPDAI scores from month 1 to 12 (Table 2
and Fig. 1c).
DAS28–3(CRP)
For the non-disease-specific comparator included here,
mean DAS28–3(CRP) at baseline was 4.38 to 4.67 across
studies and treatment groups (Table 2). Patients recei-
ving tofacitinib at either dose showed significant
improvements from baseline in DAS28–3(CRP) versus
placebo as early as week 2, which continued through the
placebo-controlled period to month 3 in both studies
(Additional file 1: Table S1). LS mean change from
baseline in DAS28–3(CRP) continued to decrease with
tofacitinib treatments through month 6 in both studies,
and improvement was maintained until the end of the
12-month OPAL Broaden study (Additional file 1:
Table S1). Patients who advanced from placebo to
tofacitinib treatments at month 3 showed improvements
from baseline in DAS28–3(CRP) and LS mean change
from baseline in DAS28–3(CRP) similar to patients re-
ceiving tofacitinib 5 or 10 mg BID throughout the studies
at month 12 in OPAL Broaden and month 6 in OPAL
Beyond (Additional file 1: Table S1).
Effect sizes and standardized response means
Based on the proposed levels of responsiveness, the
effect sizes and standardized response means for all
treatments across all composite endpoints were large
(≥0.80). The effect size for the composite endpoints was
highest for PASDAS across all treatment groups at
months 3, 6, and 12 in OPAL Broaden and months 3
and 6 in OPAL Beyond and was lowest for DAPSA
across treatments, studies, and time points, with the ex-
ception of the adalimumab group in OPAL Broaden at
month 3, in which the effect size for both DAPSA and
CPDAI was 1.05 (Table 3). Effect size increased with
time on treatment across endpoints, studies, and treat-
ment (Table 3). The effect size for all endpoints was
higher in the OPAL Broaden study compared with
OPAL Beyond at both months 3 and 6 with both tofaci-
tinib doses, with the exception of CPDAI with tofacitinib
5 mg BID, which was lower (Table 3).
The highest standardized response mean was observed
for PASDAS at months 3 and 6 in OPAL Beyond and at all
time points with tofacitinib treatment at either dose in
Fig. 2 PASDAS response rates for patients with baseline PASDAS >3.2 (FAS). *P≤0.05, ***P<0.001 versus placebo. PASDAS response was defined as
the percentage of patients who had a PASDAS score≤3.2 and a decrease from baseline in PASDAS score≥1.6 at the relevant time point. A
missing PASDAS response at a given time point was imputed as non-response. Abbreviations: BID twice daily, FAS full analysis set, N number of
patients with baseline PASDAS >3.2 in the FAS, OPAL Oral Psoriatic Arthritis triaL, PASDAS Psoriatic Arthritis Disease Activity Score, Q2W once every
2 weeks, SC subcutaneous, SE standard error
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OPAL Broaden (Table 3). In OPAL Broaden, with adali-
mumab treatment, the highest standardized response
mean was observed for PASDAS at month 3 and for
DAS28–3(CRP) at months 6 and 12 (Table 3). In both
OPAL Broaden and OPAL Beyond, the standardized re-
sponse mean increased with time on treatment in pa-
tients receiving tofacitinib 5 mg BID for all endpoints,
and for patients receiving tofacitinib 10 mg BID, with the
exception of DAS28–3(CRP) and DAPSA at month 6 in
OPAL Beyond (Table 3). The standardized response mean
for PASDAS, DAS28–3(CRP), and DAPSA was higher in
the OPAL Broaden study compared with OPAL Beyond at
both months 3 and 6 with both tofacitinib doses (Table 3).
For CPDAI, the standardized response mean was lower at
month 3 in OPAL Broaden versus OPAL Beyond with
both tofacitinib doses; at month 6, the standardized re-
sponse mean was higher with tofacitinib 5 mg BID and
lower with tofacitinib 10 mg BID in OPAL Broaden versus
OPAL Beyond (Table 3).
Outcomes stratified by MDA response and multiple
regression analysis
Mean changes from baseline appeared greater in MDA
responders than MDA non-responders for all composite
endpoints across all time points and treatments;
however, no statistical comparison was made between
these groups (Fig. 3 and Additional file 2: Table S2).
Multiple logistic regression analysis of MDA response
indicated that in both OPAL Broaden and OPAL Beyond
there were statistically significant associations between
change from baseline in PASDAS and MDA response at
all time points in both studies for both doses of tofaciti-
nib except month 3 for tofacitinib 10 mg BID (Table 4).
For DAPSA, statistically significant associations were
seen for tofacitinib 5 mg BID at 12 months in OPAL
Broaden and at 6 months in OPAL Beyond. Significant
associations were also observed for tofacitinib 10 mg
BID at both 3 and 6 months in OPAL Beyond. In con-
trast, there were no statistically significant associations
within CPDAI at any time point in either study. For
comparison, statistically significant associations were
noted for tofacitinib 10 mg BID at 6 and 12 months in
OPAL Broaden and at 3 and 6 months in OPAL Beyond
for DAS28–3(CRP).
Discussion
In the phase 3 studies OPAL Broaden and OPAL
Beyond, patients with active PsA receiving tofacitinib
5 and 10 mg BID showed improvements versus placebo
throughout the 3-month placebo-controlled period for
Table 3 Effect sizes and standardized response means across studies
Effect size Standardized response mean
OPAL Broaden OPAL Beyond OPAL Broaden OPAL Beyond
Tofacitinib
5 mg BID
N = 68
Tofacitinib
10 mg BID
N = 62
Adalimumab
40 mg SC Q2W
N = 66
Tofacitinib
5 mg BID
N = 64
Tofacitinib
10 mg BID
N = 62
Tofacitinib
5 mg BID
N = 68
Tofacitinib
10 mg BID
N = 62
Adalimumab
40 mg SC Q2W
N = 66
Tofacitinib
5 mg BID
N = 64
Tofacitinib
10 mg BID
N = 62
Month 3
PASDAS 1.73 2.40 1.69 1.53 1.84 1.42 1.75 1.73 1.26 1.53
DAPSA 0.90 1.23 1.05 0.81 0.84 1.05 1.25 1.47 0.94 1.15
CPDAI 1.03 1.53 1.05 1.41 1.45 0.89 1.27 1.11 1.11 1.49
DAS28–3(CRP) 1.47 1.77 1.37 1.07 1.16 1.25 1.46 1.50 1.14 1.29
Month 6
PASDAS 2.17 2.81 1.98 1.88 2.10 1.76 2.11 1.64 1.49 1.74
DAPSA 1.15 1.43 1.24 0.97 0.92 1.18 1.34 1.43 1.11 0.94
CPDAI 1.53 1.88 1.44 1.65 1.75 1.52 1.52 1.25 1.23 1.55
DAS28–3(CRP) 1.93 2.11 1.68 1.34 1.23 1.47 1.68 1.79 1.43 1.28
Month 12
PASDAS 2.51 3.05 2.07 – – 2.10 2.21 1.60 – –
DAPSA 1.50 1.57 1.30 – – 1.60 1.41 1.36 – –
CPDAI 1.95 2.12 1.59 – – 1.59 1.64 1.33 – –
DAS28–3(CRP) 2.25 2.18 1.77 – – 1.69 1.65 1.71 – –
N = number of patients in the full analysis set with baseline psoriasis body surface area affected greater than or equal to 3% and with no missing values for any of
the composite endpoints at baseline and months 3, 6, and 12 (OPAL Broaden only for month 12). This subset of patients was used for the calculation of effect
sizes and standardized response means
Abbreviations: BID twice daily, CPDAI Composite Psoriatic Disease Activity Index, DAPSA Disease Activity Index for Psoriatic Arthritis, DAS28–3(CRP) 3-component
Disease Activity Score using 28 joints with C-reactive protein, OPAL Oral Psoriatic Arthritis triaL, PASDAS Psoriatic Arthritis Disease Activity Score, Q2W once every
2 weeks, SC subcutaneous
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the composite endpoints assessed. These improvements
were subsequently maintained to month 6 in OPAL Be-
yond and month 12 in OPAL Broaden. Adalimumab had
comparable efficacy to tofacitinib across the composite
endpoints in OPAL Broaden.
OPAL Broaden and OPAL Beyond involved two dis-
tinct populations of patients with PsA: csDMARD-IR/
TNFi-naïve patients in OPAL Broaden and TNFi-IR pa-
tients in OPAL Beyond. Despite the difference in patient
populations, baseline values for the composite endpoints
were broadly similar across studies and treatments.
Generally, LS mean changes from baseline were greater,
and the effect size and standardized response mean were
higher, in the OPAL Broaden study compared with
OPAL Beyond. This suggests that the TNFi-naïve pa-
tients in OPAL Broaden showed more marked treatment
responses than the TNFi-IR patients in OPAL Beyond,
similar to previous reports for PsA treatment [18–20].
PASDAS baseline scores in OPAL Broaden were com-
parable with values reported in an equivalent study popu-
lation [3]; however, along with the PASDAS baseline
scores in OPAL Beyond, they were somewhat higher than
those reported in a study of standard care [21] and pa-
tients in clinical practice [22]. In the GRACE (GRAPPA
Composite Exercise) study, designed to develop composite
disease activity and responder measures for PsA, a mean
score of 5.30 for PASDAS was reported for patients chan-
ging treatment and this was taken as a surrogate for high
disease activity [11]. The mean baseline PASDAS levels re-
ported in this study were therefore suggestive of high dis-
ease activity in both OPAL Broaden and OPAL Beyond,
and following 3 months of treatment, PASDAS levels
dropped below this threshold. In addition, the GRACE
study defined a good response as a PASDAS score of less
than or equal to 3.2, following a decrease in score of
greater than or equal to 1.6 from baseline [17]; in this
study, this was achieved at month 12 in OPAL Broaden by
44.2% and 47.5% of patients receiving tofacitinib 5 and
10 mg BID, respectively, and at month 6 in OPAL Beyond
by 28.5% and 28.9% of patients receiving tofacitinib 5 and
10 mg BID, respectively. Of note, a PASDAS score of less
than or equal to 3.2 has been defined as low disease activ-
ity [17] and less than or equal to 1.9 as very low disease
activity [23].
OPAL Broaden DAPSA baseline scores were
slightly lower than baseline scores in an equivalent
study population [3] but higher than reported in
clinical practice [24]. In the GRACE study, patients
changing treatment (considered to have high disease
activity) had a mean DAPSA score of 41.91 [11],
suggesting that patients in OPAL Broaden and OPAL
Beyond had high levels of disease activity. Indeed, in
a recent study analyzing data from 30 patients with
PsA in an observational database, the cutoff for a
a
b
c
d
Fig. 3 Change from baseline in composite endpoint scores by
MDA response status across studies, a PASDAS, b DAPSA, c CPDAI,
d DAS28-3 (CRP). For complete data, see Additional file 2: Table S2.
MDA response was defined as five of the following seven criteria
being met: TJC ≤1, SJC ≤1, Psoriasis Area and Severity Index
score ≤1 or psoriasis BSA ≤3%, patient arthritis pain (VAS) ≤15 mm,
patient’s global assessment of arthritis (VAS) ≤20 mm, HAQ-DI ≤0.5,
tender entheseal points (using LEI) ≤1. Abbreviations: BID twice daily,
BSA body surface area, CPDAI Composite Psoriatic Disease Activity
Index, DAPSA Disease Activity Index for Psoriatic Arthritis, DAS28–3(CRP)
3-component Disease Activity Score using 28 joints with C-reactive
protein, FAS full analysis set, HAQ-DI Health Assessment Questionnaire-
Disability Index, LEI Leeds Enthesitis Index, MDA minimal disease
activity, OPAL Oral Psoriatic Arthritis triaL, PASDAS Psoriatic Arthritis
Disease Activity Score, Q2W once every 2 weeks, SC subcutaneous,
SJC swollen joint count, TJC tender joint count, VAS visual analog scale
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DAPSA score indicating high disease activity was
greater than 28 [25]. In this study, mean DAPSA
scores were below the high disease activity score re-
ported in the GRACE study after 3 months of active
treatment in all groups [11].
In contrast to the findings with the other composite
measures, the baseline CPDAI scores reported for OPAL
Broaden and OPAL Beyond were somewhat lower than
mean CPDAI score of 11.65 reported for patients chan-
ging treatment (surrogate for high disease activity) in the
GRACE study [11]; thus, CPDAI scores did not appear
to indicate patients with high baseline disease activity in
these patient populations. However, another study has
suggested a high disease activity threshold of greater
than 7 for CPDAI [26]; mean CPDAI scores were below
this threshold after 3 months of active treatment across
all groups and both studies.
The DAS28–3(CRP) was included for comparative
purposes only. Baseline DAS28–3(CRP) scores were
somewhat higher than the mean DAS28–3(CRP) score
of 3.96 observed for patients changing treatment (a sur-
rogate for high disease activity) in the GRACE study
[11]; however, DAS28–3(CRP) scores in this study were
reduced below this level following 3 months of treat-
ment. It should be noted, however, that this measure
was developed and validated for rheumatoid arthritis
and there are several reasons why it is inappropriate as a
composite measure for assessing PsA, particularly as it
measures only articular outcomes and excludes joints of
the foot and ankle, potentially missing important inflam-
matory disease [27].
All reported effect size and standardized response
mean values were greater than 0.80, the value generally
taken to indicate a large treatment effect or response [3].
The largest effect size was observed at all time points
and treatments for the composite endpoint PASDAS;
this is consistent with findings reported for golimumab
[3]. Effect size and standardized response mean generally
showed increases with time on treatment, indicating that
the composite endpoints demonstrated time-dependent
improvement, as might be expected. Analysis of the
percentage of PASDAS responders over time also
demonstrated the ability of the PASDAS instrument to
detect treatment-related changes in PsA disease activity.
The definition of MDA using the criteria applied in this
analysis and in previous tofacitinib publications [9, 10] has
Table 4 Comparison of associations of composite endpoints with MDA response across time points and studies
OPAL Broaden OPAL Beyond
Tofacitinib 5 mg BID
N = 68
Tofacitinib 10 mg BID
N = 62
Adalimumab 40 mg SC Q2W
N = 66
Tofacitinib 5 mg BID
N = 64
Tofacitinib 10 mg BID
N = 62
STB R STB R STB R STB R STB R
Month 3
PASDAS −0.73* −0.19 −0.71 −0.13 −0.70* −0.20 −1.23** −0.26 −0.53 0.00
DAPSA 0.64 0.10 0.09 0.00 0.35 0.00 0.38 0.00 0.87* 0.23
CPDAI −0.07 0.00 0.15 0.00 −0.33 −0.02 0.17 0.00 −0.71 −0.16
DAS28–3(CRP) −0.58 −0.06 −0.34 0.00 −0.11 0.00 −0.08 0.00 −0.75* −0.22
Month 6
PASDAS −0.91* −0.20 −0.83* −0.17 −0.61 −0.12 −1.27* −0.21 −0.77* −0.16
DAPSA 0.78 0.15 0.83 0.15 0.47 0.04 0.82* 0.21 1.00** 0.26
CPDAI 0.08 0.00 −0.00 0.00 −0.17 0.00 −0.48 0.00 0.04 0.00
DAS28–3(CRP) −0.53 −0.08 −1.23** −0.26 −0.42 −0.11 −0.44 0.00 −0.69* −0.20
Month 12
PASDAS −1.02** −0.29 −0.87* −0.18 −1.88*** −0.35 – – – –
DAPSA 0.79** 0.24 0.51 0.04 0.86 0.11 – – – –
CPDAI 0.08 0.00 −0.09 0.00 −0.00 0.00 – – – –
DAS28–3(CRP) −0.68* −0.20 −0.75* −0.19 −0.18 0.00 – – – –
*P≤0.05, **P<0.01, ***P<0.001 testing the null hypothesis that the slope coefficient is equal to 0, based on the Wald statistic from the multiple logistic
regression model
N = number of patients included in the multiple logistic regression model
For a given time point and treatment group, a multiple logistic regression was performed on MDA evaluated at this time point as a dependent variable and the
changes from baseline in the composite endpoints measured at the same time point as predictors. The slope coefficient for a composite endpoint from this
regression model is standardized (STB) to permit comparison of the associations of these composite endpoints with the MDA response. An additional statistic,
logistic pseudo partial correlation (R, range − 1 to 1), was also computed as a measure of correlation between the composite endpoints and MDA response [15]
Abbreviations: BID twice daily, CPDAI Composite Psoriatic Disease Activity Index, DAPSA Disease Activity Index for Psoriatic Arthritis, DAS28–3(CRP) 3-component
Disease Activity Score using 28 joints with C-reactive protein, MDA minimal disease activity, OPAL Oral Psoriatic Arthritis triaL, PASDAS Psoriatic Arthritis Disease
Activity Score, Q2W once every 2 weeks, SC subcutaneous
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utility for identifying treatment response and as such may
be used as a target to guide treatment decisions [16].
When the standardized slope coefficients of the composite
endpoints (STBs) from a multiple logistic regression
model were compared, the change in PASDAS had the
largest magnitude of association with MDA response
among all the composite endpoints examined, suggesting
that it had the strongest predictive ability compared with
DAPSA and CPDAI; CPDAI had the lowest predictive
ability of the endpoints.
The differing findings with respect to tofacitinib treat-
ment for the three disease-specific composite endpoints
considered in this analysis could have resulted from the
different composition of the endpoints evaluated. The
PASDAS and CPDAI both include assessment of the
skin manifestations of PsA (the PASDAS by inclusion of
the patient’s global “arthritis and psoriasis” VAS) and the
severity of enthesitis and dactylitis as well as TJC and
SJC. DAPSA, however, is focused on TJC and SJC, with
no consideration of skin disease, enthesitis, or dactylitis
and an arthritis-focused global score. The PASDAS and
CPDAI also both incorporate PROs; the PASDAS incor-
porates the PCS score of the SF-36v2 acute, and the
CPDAI the DLQI and ASQoL. In this analysis, the PAS-
DAS appeared to be the most sensitive to improvements
in the signs and symptoms of PsA related to treatment
with tofacitinib and adalimumab; the effect size observed
with the PASDAS was higher than for any other end-
point at all time points in both studies. The ability of
the PASDAS to detect change in these two studies
might reflect the components of the measure; skin
manifestations, enthesitis, dactylitis, and PROs all
appeared to be sensitive to treatment-related changes
in OPAL Broaden and OPAL Beyond, although the
adoption of a hierarchical testing scheme for key
secondary endpoints precluded demonstration of sig-
nificance for all measures and time points [9, 10].
The CPDAI also incorporates skin, enthesitis, dactyli-
tis, and PROs but appeared less sensitive to treatment
differences than PASDAS though with generally
higher effect size and standardized response mean
than DAPSA. Inclusion of the axial disease domain in
CPDAI (which does not feature in the other compo-
site endpoints assessed) could offer an explanation as
to why tofacitinib had the least impact on this com-
posite; it may be that axial disease responds to a
lesser extent than the other domains to treatment
with tofacitinib and this may have impacted the final
composite score. The CPDAI may also be less respon-
sive because of the way it is constructed: the CPDAI
is essentially a categorical measure re-expressed as a
continuous scale and the hierarchical thresholds may
blunt responsiveness. As previously discussed, the
utility of DAS28–3(CRP) is limited because of the
small number of components included in the com-
posite and the lack of inclusion of measures of skin
disease, enthesitis, dactylitis, or PROs.
It is clear from these analyses that PASDAS has su-
perior performance in this context and it has already
been reported that the consensus view is that PASDAS
should be the outcome measure of choice in PsA
clinical trials [28]. The DAPSA is easier to evaluate but
there are arguments against this measure; PsA is a
complex multifaceted disease which requires appropri-
ate evaluation across domains, and measures such as
the DAPSA, though easy to perform in practice, do not
fulfill this function. In terms of clinical practice, the
PASDAS does provide a challenge in both acquiring
the data and processing the result: the first challenge
represents the general case of clinical assessment in
PsA; the second challenge is easily overcome by the
use of predefined spreadsheets and web-based
resources.
This analysis had a number of limitations. The OPAL
Broaden and OPAL Beyond studies were not designed
for evaluation of the composite endpoints’ longitudinal
validity and sensitivity to change. In addition, for the cal-
culation of effect size and standardized response mean,
only patients with greater than or equal to 3% psoriasis
BSA affected at baseline were included, with no missing
values of the composite endpoints across multiple visits.
Consequently, patient numbers were relatively low in
some cases; CPDAI data were available for only 63% and
52% of patients receiving tofacitinib 10 mg BID in OPAL
Broaden at month 12 and OPAL Beyond at month 6, re-
spectively, and effect size and standardized response
mean were calculated in only 47–64% of patients. Also,
there was no adjustment for multiplicity; therefore,
the P values reported for comparison with placebo
should be considered nominal.
Conclusions
Overall, while the merits of specific composite measures
for assessing PsA status are under discussion [29], this
evaluation of three different composite scales for the
assessment of tofacitinib efficacy in PsA supports the
use of sensitive composite measures, particularly PAS-
DAS, for the evaluation of efficacy of treatments that
impact multiple PsA disease domains.
Additional files
Additional file 1: Table S1. Least squares (LS) mean change from
baseline in composite endpoint scores (full analysis set, or FAS).
(DOCX 44 kb)
Additional file 2: Table S2. Change from baseline in composite
endpoint scores by minimal disease activity (MDA) response status across
studies. (DOCX 39 kb)
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Abbreviations
ACR20: Greater than or equal to 20% improvement according to the criteria
of the American College of Rheumatology; ASQoL: Ankylosing Spondylitis
Quality of Life; BID: Twice daily; BSA: Body surface area; CPDAI: Composite
Psoriatic Disease Activity Index; CRP: C-reactive protein; csDMARD: Conventional
synthetic disease-modifying anti-rheumatic drug; DAPSA: Disease Activity Index
for Psoriatic Arthritis; DAS28–3(CRP) : 3-component Disease Activity Score using
28 joints with C-reactive protein; DLQI: Dermatology Life Quality Index; FAS: Full
analysis set; GRACE: GRAPPA Composite Exercise; GRAPPA: Group for Research
and Assessment of Psoriasis and Psoriatic Arthritis; HAQ-DI: Health Assessment
Questionnaire-Disability Index; IR: Inadequate responders; JAK: Janus kinase;
LEI: Leeds Enthesitis Index; LS: Least squares; MDA: Minimal disease activity;
OPAL: Oral Psoriatic Arthritis triaL; PASDAS: Psoriatic Arthritis Disease Activity
Score; PASI: Psoriasis Area and Severity Index; PCS: Physical component
summary; PRO: Patient-reported outcome; PsA: Psoriatic arthritis; Q2W: Once
every 2 weeks; SC: Subcutaneous; SD: Standard deviation; SE: Standard error;
SF-36v2: 36-item short-form survey version 2; SJC: Swollen joint count; TJC: Tender
joint count; TNFi: Tumor necrosis factor inhibitor; VAS: Visual analog scale
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